2020 Conferences | CLL Society

iwCLL 2019: Dr. Andy Rawstron on minimal residual disease (MRD) testing for chronic lymphocytic leukemia (CLL)

iwCLL 2019: Dr. Andy Rawstron on minimal residual disease (MRD) testing for chronic lymphocytic leukemia (CLL)... Details

ASH 2019: Dr. Brian Koffman on our Expert Access™ Program for patients with chronic lymphocytic leukemia (CLL)

ASH 2019: Dr. Brian Koffman on our Expert Access™ Program for patients with chronic lymphocytic leukemia (CLL) ... Details

ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL)

The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard... Details

ASH 2019 MRD Testing: Dr. Chaitra Ujjani’s short video explains the concept of MRD testing and its value in predicting progression free survival.

ASH 2019 MRD Testing: Dr. Chaitra Ujjani’s short video explains the concept of MRD testing and its value in predicting... Details

ASH 2019: Dr. Parikh Discusses Clinical Trial of Early Intervention in High-Risk CLL Patients

ASH 2019, Dr. John Pagel interviews Dr. Sameer Parikh regarding a clinical trial out of all locations of the Mayo... Details

ASH 2019: Dr. Furman Discusses Bruton’s Tyrosine Kinase Inhibitors Evolution

ASH 2019 Drs. Brian Koffman and Richard Furman discuss the effectiveness and tolerability of covalent irreversible BTK inhibitors such as... Details

ASH 2019: Dr. Anthony Mato on LOXO-305 for Chronic Lymphocytic Leukemia (CLL)

During this ASH 2019 interview, Dr. Anthony Mato discusses data he presented on LOXO-305. This selective, reversible (non-covalent) BTK inhibitor... Details

ASH 2019: Dr. Paul Barr on the combination of umbralisib, ublituximab, and venetoclax for treatment of chronic lymphocytic leukemia (CLL)

ASH 2019: Dr. Paul Barr on the combination of umbralisib, ublituximab, and venetoclax for treatment of chronic lymphocytic leukemia (CLL)... Details

ASH 2019: Dr. Nitin Jain on the combination of ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL)

At ASH 2019, Dr. Brian Koffman interviewed Dr. Nitin Jain about recent results from a clinical trial testing the combination... Details

ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients

ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients... Details